Literature DB >> 1084903

Cellular specificity of plasmacytoma-induced immunosuppression.

S Zolla-Pazner, B Sullivan, D Richardson.   

Abstract

The pattern of immunodeficiency in plasmacytoma-bearing mice appears to be unique. Mice bearing these tumors exhibit a severe impairment in their ability to mount a primary immune response to thymus-dependent and -independent antigens. However, cell-mediated immune functions in these mice apparently remain intact. Thus, when T cell activity of lymph node cells from plasmacytoma-bearing mice was tested in vivo by sensitization with dinitrofluorobenzene and in vitro by responsiveness to phytohemmagglutinin, allogeneic cells, and dinitrobenzene sulfonate, cell-mediated immunity was found to be normal.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1084903

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  The effect of an IgM plasmacytoma (TEPC-183) on the primary immune response of BALB/c mice.

Authors:  H F Havas; G Schiffman
Journal:  Immunology       Date:  1978-01       Impact factor: 7.397

2.  Immunosuppression in plasmacytoma: induction of suppressor cells.

Authors:  Y Chen; L T Hwang; P Heller
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

3.  PWM-induced generation of immunoglobulin-secreting cells in patients with multiple myeloma.

Authors:  G Sieber; B Enders; H Rühl
Journal:  Klin Wochenschr       Date:  1981-10-01

4.  Effect of plant lectins on murine myeloma cells.

Authors:  T F Warner; R G Krueger
Journal:  Br J Exp Pathol       Date:  1979-10

5.  Physiology of IgD. IV. Enhancement of antibody production in mice bearing IgD-secreting plasmacytomas.

Authors:  B Xue; R Coico; D Wallace; G W Siskind; B Pernis; G J Thorbecke
Journal:  J Exp Med       Date:  1984-01-01       Impact factor: 14.307

6.  Lymphocyte defect in plasmacytoma-bearing mice.

Authors:  I Brus; J Brent; V P Hollander
Journal:  Br J Cancer       Date:  1978-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.